Recombinant Human WT1 Protein (Thr317-Gln446), N-His tagged

• Cat.No.: WT1-6572H
• Product Overview: Recombinant human WT1 (Thr317-Gln446) fused with the N-His tag was expressed in E. coli.

Specification

• Source: E. coli
• Species: Human
• Tag: His
• Form: Lyophilized powder/frozen liquid
• Molecular Mass: 18.10 kDa
• Protein length: Thr317-Gln446
• Purity: > 90 % as determined by SDS-PAGE
• Notes: For research use only.
• Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 centigrade for one week. Store at -20 to -80 centigrade for twelve months from the date of receipt.
• Storage Buffer: 0.01M PBS, pH 7.4, 0.02 % NLS
• Reconstitution: Reconstitute in sterile water for a stock solution.
• Shipping: They are shipped out with dry ice/blue ice unless customers require otherwise.

Gene Information

• Gene Name: WT1 Wilms tumor 1 [ Homo sapiens (human) ]
• Official Symbol: WT1
• Synonyms: WT1; Wilms tumor 1; GUD; Wilms tumor protein; AWT1; WAGR; WIT 2; amino-terminal domain of EWS|last three zinc fingers of the DNA-binding domain of WT1; WT33; NPHS4; WIT-2; EWS-WT1
• Gene ID: 7490
• mRNA Refseq: NM_000378
• Protein Refseq: NP_000369
• MIM: 607102
• UniProt ID: P19544

Reviews

10/10/2020

It has been widely employed in protein electron microscopy structure analysis, where it has demonstrated remarkable efficacy.

10/25/2019

Broad applicability make it a valuable asset for a wide range of research endeavors.

05/07/2017

Researchers can rely on the WT1 Protein to deliver reliable and reproducible results, facilitating robust data interpretation and scientific advancements.

Q&As

What therapeutic strategies are being explored for cancers with abnormal WT1 expression?

Targeted therapies and immunotherapies aimed at inhibiting or modulating WT1 expression are being investigated for their potential in cancer treatment.

In what other cancers is the WT1 protein targeted for diagnostic purposes?

Apart from Wilms' tumor, WT1 is examined in leukemia, mesothelioma, and some solid tumors as a diagnostic marker.

Can WT1 be a target for personalized cancer therapy?

Yes, understanding the WT1 status in a patient's cancer can guide the development of personalized treatment plans, potentially improving outcomes.

Are there any ongoing clinical trials focused on the WT1 protein and cancer?

Yes, there are several clinical trials exploring the role of WT1 as a therapeutic target and its potential in cancer treatment.

How does the WT1 protein contribute to the prognosis of cancer patients?

High levels of WT1 expression are often associated with poor prognosis in various cancers, indicating a more aggressive disease course.